Companies › Tango Therapeutics
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TNG456 selective PRMT5 inhibitor | PRMT5 | Phase 1 | Non Small Cell Lung Cancer | Mar 2027 |
| RMC-9805 RAS(ON) G12D selective covalent inhibitor | KRAS | Phase 1 | PDAC | Jun 2027 |
| TNG462 Selective PRMT5 inhibitor | PRMT5 | Phase 1 | Locally Advanced Solid Tumor; PDAC | Jun 2027 |
| TNG260 CoREST inhibitor | – | Phase 1 | Non Small Cell Lung Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05887492 | TNG260 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Sep 2026 |
| NCT06810544 | TNG456 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Mar 2027 |
| NCT05732831 | TNG462 | Phase 1 | Locally Advanced Solid Tumor | Oncology | Jun 2027 |
| NCT06922591 | TNG462 | Phase 1 | PDAC | Oncology | Jun 2027 |
| NCT06922591 | RMC-9805 | Phase 1 | PDAC | Oncology | Jun 2027 |
Cash and short-term investments of $978m on 2026-09-30; operating cash outflow about $162m a year; runway about 73 months at that burn, to Oct 2032
Press releases filed as 8-K in the last year:
Held by 18 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Revolution Medicines Bristol-Myers Squibb Amgen TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bayer Novartis Astellas
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.